CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development...
DENVER, June 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one of the most significant periods in its corporate history after securing...
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development,...
International Regulatory Validation Has Preceded Several Recent FDA Success Stories, Though Significant Development Risks RemainHouston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings...
DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) – NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer, as it advances multiple...
Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection...
New Funding Structure Includes Redemption Rights, Ownership Limitations, and Conversion Floor as Investors Monitor Upcoming Clinical UpdatesHouston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies...
NeOnc Technologies Advances Novel Neuro-Oncology Therapies Targeting Glioblastoma and Other Hard-to-Treat Brain CancersHouston, Texas--(Newsfile Corp. - June 9, 2026) - For years, artificial intelligence...
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud...
DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – NeOnc Technologies (NASDAQ: NTHI ), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS)...